Moderna receives $590 million in federal funding from the United States to accelerate the development of a pandemic influenza vaccine

On January 17th, Moderna announced that it received $590 million in funding from the U.S. Department of Health and Human Services to accelerate the development of a pandemic influenza vaccine. Moderna stated that this funding will provide additional support for the late-stage development and licensing of a pre-pandemic vaccine based on mRNA technology and will be used to expand clinical studies targeting up to five other pandemic influenza subtypes